NEW YORK (GenomeWeb) – Abbott today announced the US Food and Drug Administration approved its RealTime CMV molecular test, the only commercially available cytomegalovirus test that can amplify two select regions of the CMV genome, according to the company.

The dual target capability of the assay reduces the risk of underquantitation or failure to detect the virus, a known concern with CMV infections because of possible mutations of the virus, Abbott said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.